Skip to content
Medical Health Aged Care

Researcher’s work on ‘kiss of death’ protein gets industry accolades

GSK Australia 4 mins read
Professor David Komander, the recipient of the 2023 GSK Award for Research Excellence

Professor David Komander – Head of the Ubiquitin Signalling Division at WEHI – has won the 2023 GSK Award for Research Excellence (ARE), in recognition of his work in elevating global understanding of the ubiquitin system.


As a leading structural biologist, Professor Komander uncovered the key principles in ubiquitin chain assembly and disassembly. Ubiquitin is a protein that acts like a ‘tag’ to tell our cells which proteins to break down or recycle, an important ‘kiss of death’ process that helps our cells stay healthy and functional.1,2 Professor Komander’s discoveries have allowed researchers to visualise different types of ubiquitin chains involved in recognition and disassembly of damaged proteins. This has led to new drug discovery projects across a range of conditions, including cancer, rare inflammatory diseases, and Parkinson’s disease.


In particular, the study of linear ubiquitin chains and their role in inflammation processes, has led the researcher to the discovery of a new protein that helps control inflammation, which was named OTULIN. This discovery further resulted in identification of a severe autoinflammatory disease, which has been named the OTULIN-related autoinflammatory syndrome (ORAS). ORAS is a very rare genetic disease, which can be life-threatening if not treated.3


Professor Komander and his team have recently been researching the link between early onset Parkinson's disease, a chronic and progressive disorder of the nervous system, and two proteins called PINK1 and Parkin as part of their studies into the ubiquitin system.


“Early onset Parkinson’s can be caused by genetic mutations that alter the function of key proteins. By understanding the molecular structures of these mutated proteins and monitoring how these proteins become activated and function, we have gained powerful insights into how Parkinson’s disease develops. Along the way, we contributed to some of the most important breakthroughs in the field in the last decade,” says Professor Komander.


Professor Komander’s research in this field has sparked collaborative work in the WEHI Parkinson’s Disease Research Centre. The centre works with movement disorder clinicians and consults with the Parkinson’s community to better understand the needs of those living with Parkinson’s and to guide research.


“Parkinson’s is the second most prevalent neurodegenerative condition, but its incidence is increasing faster than other neurological disorders. Importantly, there are no drugs that can stop disease progression,” says Associate Professor Grant Dewson, Head of the Parkinson’s Disease Research Centre.


“Defects in ubiquitin signalling are at the heart of neurodegenerative diseases such as Parkinson’s. David’s research has provided key insights into this and the role of PINK1 and Parkin in this highly complex disease. These proteins are the focus of international drug discovery efforts to stop or slow the progression of Parkinson’s and David’s research has unlocked this potential.”


There are estimated to be more than 200,000 people currently living with Parkinson’s disease in Australia, with one in five being diagnosed before the age of 50.4 Professor Komander says his team’s work on the ubiquitin code is paving the way for the development of new therapeutic agents to treat Parkinson’s disease, which currently has no cure.


“We are really getting out of the academic mindset and moving towards more translatable outcomes. Enhancing our knowledge in this area has the potential to drive transformative improvements in health outcomes for patients living with other incurable diseases, including cancer,” says Professor Komander.


Professor Komander says the $100,000 AUD grant that comes with the GSK Award for Research Excellence will help take their research to the next level, especially as there are many areas of ubiquitination that have been under researched.


“Expanding our research into other molecules will open an entire new realm of what ubiquitination might be able to do. This grant will provide us with critical support as we take our research to the next level and build new methods for measuring ubiquitin modifications.”


“It’s an exciting time to be working within the field of ubiquitination. I am honoured to be named the 2023 recipient of the GSK Award for Research Excellence and have our work recognised in this way.”


The 2023 GSK Award for Research Excellence (ARE) was presented to Professor Komander at Research Australia’s Health and Medical Research Awards in Sydney this week. Dr Alan Paul, Medical Director at GSK Australia, said GSK is proud to support local Australian researchers who are at the forefront of improving health outcomes for patients in Australia and around the world.


“Professor Komander’s work is an outstanding example of how home-grown innovation is transforming our understanding and potential treatment of diseases like Parkinson’s that we once believed were incurable,” said Dr Alan Paul. “We are excited to support David and his team as they continue their critical research into the ubiquitin system.”


The GSK Award for Research Excellence is one of the most prestigious and longstanding independently-judged awards available to the Australian medical research community. It has been awarded since 1980, with over $3 million* awarded to local researchers since its inception.


Among the previous recipients of the GSK Award for Research Excellence are some of Australia’s most noted scientific researchers, including Professors Rinaldo Bellomo AO and Jamie Cooper AO (2021) and Mark Febbraio (2020). The 2022 GSK Award for Research Excellence was awarded to Professor Georgia Chenevix-Trench, Distinguished Scientist at The QIMR Berghofer Medical Research Institute, for her innovative research into mapping the genetics of breast and ovarian cancer.




Enquiries or interview requests please contact:


Anastasiia Nazarenko                                        Juliette Bagwell                         

+61435 977 559                                                +61433 336 487


This media release has been issued by Palin Communications on behalf of GSK Australia.

About GSK

GSK is a science-led global healthcare company. For further information please visit



  • 2023 value calculated from the respective yearly grant by adjusting for inflation.

Key Facts:

·         Professor David Komander has won the 2023 GSK Award for Research Excellence in recognition of his work in uncovering the broad and important role the ubiquitin system plays in the human body.

·         His research focuses on a form of protein modification called ubiquitination, which marks proteins for destruction, earning it the label the ‘kiss of death’.1

·         The GSK Award for Research Excellence (ARE) is one of Australia’s most prestigious and longstanding awards available to the medical research community.


More from this category

  • Medical Health Aged Care
  • 20/04/2024
  • 04:30
Dementia Australia

Join us TODAY for Bendigo Memory Walk & Jog

What: Dementia Australia’sBendigoMemory Walk & Jog When: Saturday 20 April, from 8am Who: More than 390 locals participating on the day. People who have been impacted by dementia, their family, friends and carers. Where: Bendigo Botanic Gardens, Bendigo For more information visit: Walk or jog with us. We are in this together. Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people…

  • Contains:
  • Medical Health Aged Care, Science
  • 19/04/2024
  • 15:00
Monash University

Large-scale genetic study finds new link between Irritable Bowel Syndrome and the cardiovascular system

New research published today in the journal Cellular and Molecular Gastroenterology and Hepatology sheds light on disease mechanisms common to irritable bowel syndrome (IBS) and cardiovascular diseases (CVD). Led by Dr Leticia Camargo Tavares, a Postdoctoral Fellow at the Hypertension Research Laboratory within Monash University’s School of Biological Sciences, the study reveals novel insights into the genetic underpinnings of IBS, offering potential avenues for therapeutic intervention. IBS is one of the most prevalent gastrointestinal disorders globally, affecting up to 10 per cent of the population, with a disproportionate impact on women. It is characterised by a complex range of symptoms…

  • Medical Health Aged Care
  • 19/04/2024
  • 11:13
Gilead Sciences Australia

Australian community organisations addressing viral hepatitis receive AU$400,000 via global Gilead ALL4LIVER Grant program

– Gilead Sciences joins forces with World Hepatitis Alliance and experts to drive progress on viral hepatitis elimination targets – – Australian initiatives well represented in Gilead’s US$4 million global fund to empower local communities in the fight against viral hepatitis – Melbourne, Australia, 19 April 2024 – Today, on World Liver Day, Gilead Sciences Australia has announced nine local community organisations addressing viral hepatitis will receive a combined AU$400,000 via the global Gilead ALL4LIVER Grant. The recipients were selected by an independent external review panel of global experts, including the World Hepatitis Alliance. Australia has committed to achieving the…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.